TABLE 1.
Baseline characteristics of infused patients
| Baseline characteristics of infused patients a | N = 75 |
|---|---|
| Median age (IQR) ‐years | 60 (52–67) |
| Age ≥65 y– n (%) | 23 (31) |
| Gender –n (%) | |
| Male | 44 (59) |
| Female | 31 (41) |
| ECOG score, median (IQR) | 1 (0–1) |
| 0–n (%) | 25 (33) |
| 1–n (%) | 41 (55) |
| 2–n (%) | 5 (7) |
| Missing data –n (%) | 4 (5) |
| Histology – n (%) | |
| Diffuse large B‐cell lymphoma, NOS | 44 (58) |
| High grade B‐cell lymphoma DH/TH | 11 (15) |
| Transformed from follicular lymphoma | 17 (23) |
| Transformed from other indolent histology | 3 (4) |
| Cell of origin – n (%) | |
| GCB | 44 (59) |
| Non‐GCB | 24 (32) |
| Missing data | 7 (9) |
| Disease stage‐ n (%) | |
| Stage I‐II | 6 (8) |
| Stage III‐IV | 69 (92) |
| Extranodal disease (≥1 site)–n (%) | 60 (80) |
| Bulky disease (>7 cm)–n (%) | 30 (42) |
| LDH levels before treatment | |
| <2xULN | 51 (68) |
| ≥2xULN | 24 (32) |
| IPI prognostic score – n (%) | |
| 0–2 | 25 (33) |
| 3–5 | 46 (62) |
| Missing data | 4 (5) |
| Number of previous lines of treatment, median (IQR) | 3 (2–4) |
| 2–3 | 54 (72) |
| >3 | 21 (28) |
| Previous ASCT – n (%) | 29 (39) |
| Response to previous therapy – n (%) | |
| Primary refractory | 39 (52) |
| Refractory to last therapy | 22 (29) |
| Relapsed | 14 (19) |
| Bridging treatment ‐n (%) | 65 (87) |
| Cyclophosphamide‐Prednisone/CVP b | 29 (44) |
| Platinum‐based c | 16 (24) |
| Bendamustine‐based d | 5 (8) |
| Rituximab‐CHOP e | 3 (5) |
| Steroids | 2 (3) |
| Radiotherapy | 2 (3) |
| Rituximab‐Lenalidomide | 2 (3) |
| Other chemotherapy f | 3 (5) |
| Data not available | 3 (5) |
Abbreviations: ASCT, Autologous Stem Cell Transplant; DH/TH, Double Hit/Triple Hit; ECOG, Eastern Cooperative Oncology Group; GCB, Germinal Center B‐cell; IPI, International Prognostic Index; IQR, Interquartile range; LDH, Lactate Dehydrogenase; NOS, Not Otherwise Specified; ULN, Upper Limit of Normal.
ECOG score was missing in four patients, IPI missing in four patients; Bulky data missing in two patients, extranodal missing in one patient.
CVP, Cyclophosphamide, vincristine, and prednisolone.
Platinum‐based strategies included R‐GEMOX (12), R‐GDP (3) and R‐ESHAP (1).
Bendamustine based included Rituximab‐Bendamustine with (2) or without (3) Polatuzumab.
CHOP, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.
Other chemotherapy included MINE (Mesna, Ifosfamide, Mitoxantrone, Etoposide), R‐IE (rituximab, ifosfamide, and etoposide) and R‐hyperCVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone).